Real-World Study of TAR-200 Treatment Outcomes for Adults with Early-Stage Non-Muscle Invasive Bladder Cancer in the US

What this Trial Is About

Researchers are evaluating the real-world use and outcomes of TAR-200, a treatment for non-muscle invasive bladder cancer NMIBC, an early-stage bladder cancer confined to the inner lining of the bladder. The study aims to measure disease-free survival, or the time from the first TAR-200 insertion until cancer worsens or symptoms return. This observational study focuses on participants in the United States who have begun TAR-200 treatment in routine clinical practice. Participants with a confirmed diagnosis of NMIBC who started their first dose of TAR-200 within six weeks before the baseline visit will be observed for up to 24 months. No additional treatment or intervention is given as part of the study instead, participants are followed to monitor their outcomes over this period. The study collects information on various measures, including complete response rates, duration of response, overall and cancer-specific survival, time to next treatment, and treatment adherence. During the study, participants will have visits to track their health status and outcomes related to TAR-200 treatment. Researchers will collect data on adverse events, treatment patterns, time to treatment discontinuation, and bladder-intact survival. The primary outcome is disease-free survival measured up to 24 months. Secondary outcomes include many related measures monitored during this time. Participants remain under their usual care while being observed for study purposes, and the study aims to provide insight into how TAR-200 performs in everyday clinical settings.

A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States